Clinical trial

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

NCT07340541

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2026-02-16

PhasePHASE2

Study timeline

Study start (actual)2026-02-16Date precision: day

Registry last updated2026-09-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Metastatic Breast Cancerunresolved

Triple Negative Breast Cancerunresolved

Estrogen-receptor-positive Breast Cancerunresolved

Hormone Receptor Negative Breast Carcinomaunresolved

Interventions

SERD* + abemaciclibDRUG

SERD* + everolimusDRUG

SERD* + everolimus or capecitabineDRUG

SOCDRUG

AntiandrogenDRUG

Sponsors & collaborators

UNC Lineberger Comprehensive Cancer Centerlead sponsor

Advanced Research Projects Agency for Health (ARPA-H)collaborator

Breast Cancer Research Foundationcollaborator

Translational Breast Cancer Research Consortiumcollaborator

Mapped research locations

HoustonTexas, United States1 PhiladelphiaPennsylvania, United States1 BaltimoreMaryland, United States1 New HavenConnecticut, United States1 RochesterMinnesota, United States1 Chapel HillNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07340541 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.